Effect of Prophylactic Versus Preemptive Lamivudine Treatment and Tenofovir on HBsAg (+) Kidney Transplant Recipients


Ruhi C. , SÜLEYMANLAR İ., KOÇAK H., Dinckan A., Ersoy F., SÜLEYMANLAR G.

EXPERIMENTAL AND CLINICAL TRANSPLANTATION, cilt.13, ss.35-40, 2015 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 13 Konu: 1
  • Basım Tarihi: 2015
  • Doi Numarası: 10.6002/ect.2013.0280
  • Dergi Adı: EXPERIMENTAL AND CLINICAL TRANSPLANTATION
  • Sayfa Sayıları: ss.35-40

Özet

Objectives: Chronic hepatitis B virus infection remains a clinical problem for HBsAg (+) kidney transplant recipients. Lamivudine is the approved treatment; however, there are contrary views about optimal initiation. In case of resistance, novel nucleoside analogs should be considered but experience is limited.